Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEGONIA: durvalumab-based first-line metastatic triple-negative breast cancer study
2024-511646-40-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of durvalumab, paclitaxel, oleclumab, capivasertib, datopotamab deruxtecan and 2 more in triple-negative breast cancer (TNBC) (8 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Objective response rate. Planned start Jul 2019; status: authorised.
02
Drugs
durvalumabpaclitaxeloleclumabcapivasertibdatopotamab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-511646-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511646-40-00.